June 2026

On paper, the OCM cost Medicare millions. A decade later, physicians say its lessons are priceless.

The editor in chief of Evidence-Based Oncology calls for universal biomarker testing in every patient, the same standard set for patients in his practice.

Ohio cancer care leaders identified persistent gaps in quality, pharmacy infrastructure, bispecific access, and biomarker testing at a May 2026 summit.

An Institute for Value-Based Medicine® event in Princeton highlights how the state's leading cancer care providers meet the needs of a diverse population.

Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.

Johnetta Blakely, MD, MS, MMHC, discusses her new role as chief medical officer of the Community Oncology Alliance during an interview that will appear in the June issue of Evidence-Based Oncology.

Why colocation of mental health in community oncology practice boosts adherence, eases distress, and thrives with payer-backed reimbursement.

This review will appear in the June issue of Evidence-Based Oncology.

Texas Oncology boosts precision medicine with near-universal biomarker testing, quality measurement, and genomic insights—advancing health equity through streamlined workflows and coverage. This commentary will appear in the June issue of Evidence-Based Oncology.

Circulating tumor DNA (ctDNA) detection is linked to worse survival outcomes in resectable melanoma, but high false-negative rates limit its use in surveillance or de-escalation.

Fears that the telemedicine boom would send health care costs soaring haven’t been borne out, a major new study finds, and the timing couldn’t be more critical for federal policy makers.

An NCCN Policy Summit webinar on May 7 warned that cancer care is failing patients, as poor health literacy, misinformation, and digital overload widen gaps in understanding.